Glenmark Pharmaceuticals Ltd. (GPL) was incorporated in 1977. It was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Its branded generics business has a significant presence in markets across emerging economies including India. It is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. Its API business sells products in many countries including the US, various countries in the EU, South America and India.

India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets.

Business area of the company

The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.

Glenmark Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

Sanofi India Ltd.

Natco Pharma Ltd.

Eris Lifesciences Ltd.

Granules India Ltd.

Astrazeneca Pharma India Ltd.

Ajanta Pharma Ltd.

JB Chemicals & Pharmaceuticals Ltd.

Medplus Health Services Ltd.

Procter & Gamble Health Ltd.

Jubilant Pharmova Ltd.

Caplin Point Laboratories Ltd.

Glenmark Life Sciences Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	11,916 Cr		EPS	59.2		High	444
Stock P/E	7.1		Net Profit Margin	8.3		Low	430.5

Market Cap	11,916 Cr	ROE	12.3%
P/E Ratio(TTM)	7.1	EPS(TTM)	29.3
P/B Ratio	0.7	Dividend Yield	0.6%
Industry P/E	63.6	Book Value	623.3
		Face Value	1.0

GLENMARK